Uncategorized

Study data convince Lundbeck to push new migraine drug forward

Published

on

A possible alternative to “anti-CGRP” medications, the drug didn’t meet some analysts’ expectations in mid-stage testing but still convinced Lundbeck to pursue further development.

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version